TY  - JOUR
A1  - Argentiero, Antonella
A1  - Solimando, Antonio Giovanni
A1  - Krebs, Markus
A1  - Leone, Patrizia
A1  - Susca, Nicola
A1  - Brunetti, Oronzo
A1  - Racanelli, Vito
A1  - Vacca, Angelo
A1  - Silvestris, Nicola
T1  - Anti-angiogenesis and immunotherapy: novel paradigms to envision tailored approaches in renal cell-carcinoma
JF  - Journal of Clinical Medicine
N2  - Although decision making strategy based on clinico-histopathological criteria is well established, renal cell carcinoma (RCC) represents a spectrum of biological ecosystems characterized by distinct genetic and molecular alterations, diverse clinical courses and potential specific therapeutic vulnerabilities. Given the plethora of drugs available, the subtype-tailored treatment to RCC subtype holds the potential to improve patient outcome, shrinking treatment-related morbidity and cost. The emerging knowledge of the molecular taxonomy of RCC is evolving, whilst the antiangiogenic and immunotherapy landscape maintains and reinforces their potential. Although several prognostic factors of survival in patients with RCC have been described, no reliable predictive biomarkers of treatment individual sensitivity or resistance have been identified. In this review, we summarize the available evidence able to prompt more precise and individualized patient selection in well-designed clinical trials, covering the unmet need of medical choices in the era of next-generation anti-angiogenesis and immunotherapy.
KW  - renal cell carcinoma
KW  - angiogenesis
KW  - immune-checkpoint inhibitor
KW  - tumor microenvironment
KW  - molecular subtypes
KW  - prognostic-biomarkers
KW  - predictive factors
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-205846
SN  - 2077-0383
VL  - 9
IS  - 5
ER  - 
TY  - JOUR
A1  - Rao, Luigia
A1  - Giannico, Donato
A1  - Leone, Patrizia
A1  - Solimando, Antonio Giovanni
A1  - Maiorano, Eugenio
A1  - Caporusso, Concetta
A1  - Duda, Loren
A1  - Tamma, Roberto
A1  - Mallamaci, Rosanna
A1  - Susca, Nicola
A1  - Buonavoglia, Alessio
A1  - Da Vià, Matteo Claudio
A1  - Ribatti, Domenico
A1  - De Re, Vallì
A1  - Vacca, Angelo
A1  - Racanelli, Vito
T1  - HB-EGF−EGFR signaling in bone marrow endothelial cells mediates angiogenesis associated with multiple myeloma
JF  - Cancers
N2  - Epidermal growth factor receptor (EGFR) and its ligand heparin-binding EGF-like growth factor (HB-EGF) sustain endothelial cell proliferation and angiogenesis in solid tumors, but little is known about the role of HB-EGF–EGFR signaling in bone marrow angiogenesis and multiple myeloma (MM) progression. We found that bone marrow endothelial cells from patients with MM express high levels of EGFR and HB-EGF, compared with cells from patients with monoclonal gammopathy of undetermined significance, and that overexpressed HB-EGF stimulates EGFR expression in an autocrine loop. We also found that levels of EGFR and HB-EGF parallel MM plasma cell number, and that HB-EGF is a potent inducer of angiogenesis in vitro and in vivo. Moreover, blockade of HB-EGF–EGFR signaling, by an anti-HB-EGF neutralizing antibody or the EGFR inhibitor erlotinib, limited the angiogenic potential of bone marrow endothelial cells and hampered tumor growth in an MM xenograft mouse model. These results identify HB-EGF–EGFR signaling as a potential target of anti-angiogenic therapy, and encourage the clinical investigation of EGFR inhibitors in combination with conventional cytotoxic drugs as a new therapeutic strategy for MM.
KW  - multiple myeloma
KW  - HB-EGF
KW  - EGFR
KW  - bone marrow angiogenesis
KW  - endothelial cells
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-200786
SN  - 2072-6694
VL  - 12
IS  - 1
ER  -